- Prothena press release ( NASDAQ: PRTA ): Q4 GAAP EPS of $0.12 beats by $0.61 .
- Revenue of $49.9M (vs. $1.2M last year) beats by $20.76M .
- Total revenue for Q4 included a $40M milestone payment from Novo Nordisk ( OTCPK:NONOF ) and revenue for Q4 included BMS collaboration revenue of $9.9 million.
- Expects the full year 2023 net cash used in operating and investing activities to be $213 to $229 million and expects to end the year with approximately $512 million in cash, cash equivalents and restricted cash (midpoint).
For further details see:
Prothena GAAP EPS of $0.12 beats by $0.61, revenue of $49.9M beats by $20.76M